Search Result
Results for "
immunogenic antigen
" in MedChemExpress (MCE) Product Catalog:
8
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-157745
-
|
mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
|
-
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
-
-
- HY-109506
-
|
129Y83
|
Liposome
Endogenous Metabolite
|
Others
|
|
DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-157174
-
|
|
Others
|
Inflammation/Immunology
|
|
Mannosamine-desthiobiotin adduct (compound MDTBA) is a carrier immunogenicity-reducing hapten that reduces the immunogenicity of protein carriers upon conjugation to available free amines on the carrier protein surface. Conjugation of Mannosamine-desthiobiotin adduct to hsIgG significantly (>1-fold) reduced the immunogenicity of hsIgG. Mannosamine-desthiobiotin adduct can be used in antigen design research .
|
-
-
- HY-109506R
-
|
|
Liposome
Endogenous Metabolite
|
Others
|
|
DPPC (Standard) is the analytical standard of DPPC. This product is intended for research and analytical applications. DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
-
- HY-P1778
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
|
-
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-P1778A
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
|
-
-
- HY-W587780
-
|
SMX-NO
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Sulfamethoxazole-NO (SMX-NO) is the major immunogen in sulfonamide allergy, producing modest ascorbic acid depletion and hemoglobin adduct formation. Sulfamethoxazole-NO haptens tissue proteins and is immunogenic in rodents .
|
-
-
- HY-P10295
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
|
-
-
- HY-D1056
-
|
LPS
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥10 mg/mL. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
-
-
HY-L172
-
|
|
109 compounds
|
|
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.
MCE designs a unique collection of 109 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.
|
| Cat. No. |
Product Name |
Type |
-
- HY-109506
-
|
129Y83
|
Drug Delivery
|
|
DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-D1056
-
|
LPS
|
Carbohydrates
|
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥10 mg/mL. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
- HY-109506R
-
|
|
Drug Delivery
|
|
DPPC (Standard) is the analytical standard of DPPC. This product is intended for research and analytical applications. DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1778A
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
|
-
- HY-P1778
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
|
-
- HY-P10295
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
|
-
- HY-P5471
-
|
[Leu27]-Melan-A, MART-1 (26-35)
|
Peptides
|
Others
|
|
Melan-A/MART-1 analog ([Leu27]-Melan-A, MART-1 (26-35)) is a biological active peptide. (This Melan-A (26-35) analog, Leu substituted for Ala at position 27, shows better HLA-A*0201 binding properties as well as better immunogenicity and antigenicity than the natural Melan-A (26-35).Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-109506
-
-
-
- HY-D1056
-
|
LPS
|
Structural Classification
Polysaccharides
Microorganisms
Classification of Application Fields
Source classification
Inflammation/Immunology
Disease Research Fields
Saccharides
|
Toll-like Receptor (TLR)
|
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥10 mg/mL. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
-
- HY-109506R
-
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-157745
-
|
mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
|
-
- HY-109506
-
|
129Y83
|
|
Phospholipids
|
|
DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
